Circulating tumor DNA evaluated by Next-Generation Sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer

DOI: 10.1080/2162402X.2018.1424675

Keywords: nivolumab, circulating tumor DNA, anti-PD1, immune checkpoint inhibitor, tumor response, clinical benefit, somatic mutation, non-small cell lung cancer, next-generation sequencing

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text